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Purpose of the study
To assess the characteristics of advanced HIV-1 infected
patients with triple-class antiretroviral drug failure
(NRTIs, NNRTIs and PIs), and harbouring protease muta-
tions.
Methods
Retrospective, cross-sectional, multicenter study to iden-
tify adult patients with previous failure to NRTIs, NNRTIs
and PIs, and a genotype with at least one major PI muta-
tion plus = 4 protease mutations in all (IAS-USA guide-
lines).
Summary of results
326 patients identified by 82 treating physicians. Median
age 43 years, 80% male, median length of HIV infection
12 years, acquired by IVDU in 40%, and by sexual inter-
course in 58%. Patients had been treated with a median of
11 (IQR 9–13) drugs, five PIs, and eight (IQR 6–10) lines
of treatment. The main reason for treatment change was
virological failure. Median CD4 count 274 cells (median
nadir CD4 176 cells), viral load 12,242 HIV-1 RNA cop-
ies/ml. CDC stage was C in 58% of them. Hepatitis C co-
infection in 42%, and HBsAg-positive 5.6%. Treatment
compliance was significantly lower in IVDU vs. non-IVDU
(51% vs 72%, p = 0.0003). The most frequent major pro-
tease mutations were L90M (65%), V82A/F/S/T (60%),
M46I/L (39%), I84V (23%), and G48V (11%). L63P,
L10I, A71V, and M36I were the most frequently isolated
accessory protease mutations. Nearly all patients har-
boured M184V, different patterns of TAMs, and NNRTI
mutations that rendered inactive the first generation
NNRTIs. Their first line of treatment was composed of an
NRTI monotherapy in 44% of patients, and 55% had
received an early regimen with only dual NRTI. The first PI
was a non-boosted one in 77% of patients, and 92% have
received a boosted PI later on. Most of them had recycled
inactive drugs, mainly NRTIs, and partially active PIs.
Conclusion
Patients with advanced virological failure exposed to
NRTI, NNRTI and PI share specific characteristics that
drive a "classical" pathway to HIV-1 resistance. This pat-
tern is composed of a burned reverse transcriptase with
TAMs, M184V, NNRTI mutations, and a variety of pro-
tease mutations that render NRTI and first generation
NNRTIs and PIs inactive. Most of them started their
antiretroviral treatment with mono/dual NRTI therapy.
Their first PI was non-boosted. The late onset of a boosted
PI has not precluded the accumulation of protease resist-
ance mutations in these patients.
from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008
Published: 10 November 2008
Journal of the International AIDS Society 2008, 11(Suppl 1):P42 doi:10.1186/1758-2652-11-S1-P42
<supplement> <title> <p>Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-2652-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.jiasociety.org/content/11/S1/P42
© 2008 Llibre et al; licensee BioMed Central Ltd. 
